Fujifilm and HORIBA have collaborated on a cutting-edge gene delivery system that promises to revolutionize the production of gene therapy products. Through Fujifilm’s breakthrough continuous electroporation technology, which enhances gene delivery efficiency by up to 100 times compared to traditional methods, the new system aims to significantly boost productivity in manufacturing gene therapies. This advancement comes at a crucial time as the global cell and gene therapy market is projected to grow at a compound annual growth rate of approximately 30% through to 2030, presenting immense opportunities for innovative solutions in the field.
The gene therapy approach involves introducing functional genes into the body to address genetic disorders at their root cause. This technology is gaining traction worldwide for its potential in treating diseases that currently lack effective treatment options. Despite its promise, challenges such as technological complexities, inefficiencies in manufacturing processes, and high research and development costs hinder the widespread adoption of gene therapy. The collaboration between Fujifilm and HORIBA, leveraging their expertise in life sciences and manufacturing, aims to address these challenges by enhancing manufacturing productivity and reducing costs through their innovative gene delivery system.
Fujifilm’s continuous electroporation technology overcomes the limitations of traditional methods by using precisely controlled electrical pulses to create pores in cell membranes, allowing for direct gene delivery into cells. This approach not only significantly improves gene delivery efficiency but also offers flexibility in production scale, catering to small to large-scale manufacturing needs. By increasing productivity up to 100 times compared to batch-based methods, this system promises to streamline manufacturing processes and drive cost reductions in gene therapy production, making these therapies more accessible to patients in need.
The collaboration between Fujifilm and HORIBA builds upon their history of successful joint projects across various fields, demonstrating a shared commitment to innovation and excellence. By combining Fujifilm’s advanced technologies with HORIBA’s manufacturing expertise and global support capabilities, the partnership aims to commercialize the gene delivery system and cater to the high demand for gene therapy in North American and European markets. This joint effort not only showcases the power of collaboration in driving impactful solutions but also underscores the companies’ dedication to addressing unmet medical needs and improving healthcare outcomes globally.
Key Takeaways:
– Fujifilm and HORIBA have developed a novel gene delivery system utilizing continuous electroporation technology to enhance gene therapy manufacturing productivity.
– The system offers up to 100 times greater efficiency compared to conventional methods, aiming to reduce costs and improve accessibility to gene therapy products.
– By leveraging their respective expertise, Fujifilm and HORIBA seek to address challenges in the gene therapy field and contribute to advancing healthcare on a global scale.
Tags: gene therapy, transfection
Read more on news.marketersmedia.com